Aprepitant for the prevention of chemotherapy-induced nausea and vomiting in adolescents

Pediatr Blood Cancer. 2009 Dec 15;53(7):1357; author reply 1358. doi: 10.1002/pbc.22120.
No abstract available

Publication types

  • Letter
  • Comment

MeSH terms

  • Adolescent
  • Antiemetics / adverse effects*
  • Antiemetics / pharmacokinetics
  • Antiemetics / therapeutic use
  • Antineoplastic Combined Chemotherapy Protocols / adverse effects*
  • Antineoplastic Combined Chemotherapy Protocols / pharmacokinetics
  • Aprepitant
  • Carboplatin / administration & dosage
  • Carboplatin / adverse effects
  • Cisplatin / administration & dosage
  • Cisplatin / adverse effects
  • Cyclophosphamide / administration & dosage
  • Cyclophosphamide / adverse effects
  • Double-Blind Method
  • Drug Interactions
  • Etoposide / adverse effects
  • Etoposide / pharmacokinetics
  • Fever / etiology
  • Humans
  • Ifosfamide / adverse effects
  • Ifosfamide / pharmacokinetics
  • Incidence
  • Morpholines / adverse effects*
  • Morpholines / pharmacokinetics
  • Morpholines / therapeutic use
  • Nausea / chemically induced
  • Nausea / prevention & control*
  • Neutropenia / chemically induced*
  • Neutropenia / epidemiology
  • Randomized Controlled Trials as Topic
  • Sample Size
  • Vomiting / chemically induced
  • Vomiting / prevention & control*

Substances

  • Antiemetics
  • Morpholines
  • Aprepitant
  • Etoposide
  • Cyclophosphamide
  • Carboplatin
  • Cisplatin
  • Ifosfamide